X
TGTX icon

Xponance’s TG Therapeutics TGTX Stock Holding History

Xponance’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790K Buy
14,372
+693
+5% +$28.4K ﹤0.01% 887
2026
Q1 		$454K Buy
13,679
+2,161
+19% +$64.4K ﹤0.01% 1059
2025
Q4 		$343K Buy
11,518
+99
+0.9% +$3.23K ﹤0.01% 1108
2025
Q3 		$413K Buy
11,419
+74
+0.7% +$2.44K ﹤0.01% 1035
2025
Q2 		$408K Buy
11,345
+484
+4% +$18K ﹤0.01% 1027
2025
Q1 		$428K Buy
10,861
+543
+5% +$18.3K ﹤0.01% 983
2024
Q4 		$311K Buy
10,318
+1,326
+15% +$38.1K ﹤0.01% 1118
2024
Q3 		$210K Buy
+8,992
New +$196K ﹤0.01% 1236
2021
Q4 		– Sell
-6,021
Closed -$200K – 1196
2021
Q3 		$200K Sell
6,021
-997
-14% -$30.8K ﹤0.01% 1120
2021
Q2 		$272K Buy
+7,018
New +$276K 0.01% 1096

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Xponance's TGTX Position: Q2 2026 in Review

Xponance increased its TG Therapeutics (TGTX) stake by 5.1% in Q2 2026, buying an estimated $28.4K and bringing the position to 14,372 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Xponance first reported a position in TGTX in Q2 2021 and has held it in 10 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Xponance held 14,372 shares of TG Therapeutics worth $790K as of Q2 2026.
  • Xponance bought 693 TG Therapeutics shares in Q2 2026, an estimated $28.4K.
  • TG Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #887 holding.
  • Xponance first reported a position in TG Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.